<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421016</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No S03914</org_study_id>
    <nct_id>NCT02421016</nct_id>
  </id_info>
  <brief_title>Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)</brief_title>
  <official_title>A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus ABSORB Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The bioresorbable polymer SYNERGY EES exhibits a favourable vascular healing profile in&#xD;
      patients undergoing coronary intervention for de novo lesions. Specifically, the SYNERGY EES&#xD;
      is superior to the ABSORB bioresorbable vascular scaffold in terms of antirestenotic efficacy&#xD;
      as assessed by angiography at 6-8 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation currently&#xD;
      represents the dominant treatment strategy in patients undergoing catheter intervention.&#xD;
      However, effective neointimal suppression occurs at the cost of a systematic delay in&#xD;
      arterial healing in comparison with after bare metal stenting. This underlies a small but&#xD;
      significant increased risk of stent thrombosis after DES implantation in comparison with bare&#xD;
      metal stent implantation as well as a possible excess of in-stent neoatheroma formation. To&#xD;
      address this issue recent technological advances have focused on bioresorbable polymer&#xD;
      coatings and the development of stents with fully resorbable backbones.&#xD;
&#xD;
      Newer generation metallic DES with bioresorbable polymer coatings have been shown to improve&#xD;
      vascular healing after coronary stenting. In particular a novel thin-strut bioresorbable&#xD;
      polymer everolimus-eluting stent (EES, SYNERGY, Boston Scientific Corp., Natick, MA, USA) has&#xD;
      shown high angiographic antirestenotic efficacy as well as high clinical efficacy and safety&#xD;
      in early randomized trials. In addition, DES with bioresorbable backbones represent an&#xD;
      alternative approach to ensure short-term vessel scaffolding and drug delivery with enhanced&#xD;
      vessel healing. The everolimus-eluting bioresorbable backbone stent (ABSORB bioresorbable&#xD;
      vascular scaffold [BVS], Abbott Vascular, Santa Rosa, CA, USA) is the most-extensively&#xD;
      studied device in this class and early reports in selected patients show encouraging clinical&#xD;
      results. However requirement for thicker stent struts and more careful lesion preparation has&#xD;
      led to concerns that potential clinical benefits may be offset by erosion of early&#xD;
      antirestenotic efficacy and occurrence of clinical events related to limitations of device&#xD;
      deployment.&#xD;
&#xD;
      At present there is a lack of randomized clinical trial data examining outcomes of patients&#xD;
      treated with these two alternative strategies. The aim of the current ISAR-RESORB study is to&#xD;
      test the clinical performance of the bioresorbable-polymer SYNERGY with that of the ABSORB&#xD;
      BVS in patients undergoing PCI of de novo coronary lesions. The primary endpoint will be&#xD;
      percentage diameter stenosis at protocol-mandated 6-8 month angiographic follow-up. Secondary&#xD;
      clinical endpoint will be assessed at 12 months. Sample size calculation is based on a&#xD;
      superiority hypothesis for SYNERGY versus ABSORB BVS. It is planned to enrol a total of 230&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage diameter stenosis (in-stent) by quantitative coronary angiography analysis</measure>
    <time_frame>at 6-8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiac death/target vessel-myocardial infarction (MI)/ target lesion revascularization (TLR) (Device-oriented composite endpoint)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death/any MI/all revascularization (Patient-oriented composite endpoint)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular death or MI</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>SYNERGY EES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable polymer everolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABSORB [BVS]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting bioresorbable backbone stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY EES</intervention_name>
    <description>Bioresorbable polymer everolimus-eluting stent</description>
    <arm_group_label>SYNERGY EES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABSORB [BVS]</intervention_name>
    <description>Everolimus-eluting bioresorbable backbone stent</description>
    <arm_group_label>ABSORB [BVS]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years or older with ischemic symptoms or evidence of myocardial ischemia&#xD;
             in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2&#xD;
             lesions in 2 separate vessels)&#xD;
&#xD;
          -  Reference diameter ≥2.5 mm and ≤3.9 mm&#xD;
&#xD;
          -  Lesion length &lt;28 mm&#xD;
&#xD;
          -  Written, informed consent by the patient for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Acute ST-elevation myocardial infarction within 48 hours from symptom onset.&#xD;
&#xD;
          -  Target lesion located in left main trunk or bypass graft&#xD;
&#xD;
          -  Severe calcification of the lesion&#xD;
&#xD;
          -  Target lesion contains a side branch (diameter ≥2mm) or a bifurcation or is located 2&#xD;
             mm away from a bifurcation&#xD;
&#xD;
          -  Ostial lesions&#xD;
&#xD;
          -  Severe vessel tortuosity&#xD;
&#xD;
          -  Renal insufficiency (most recent serum creatinine within the last 72h prior to&#xD;
             randomization &gt; 2 mg/dl or 177 µmol/l)&#xD;
&#xD;
          -  Malignancies or other co-morbid conditions with life expectancy less than 12 months or&#xD;
             that may result in protocol non-compliance&#xD;
&#xD;
          -  Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding&#xD;
&#xD;
          -  Contraindications or allergy to platinum, chromium, everolimus or the inability to&#xD;
             take antiplatelet therapy for at least 6 months after stenting; known allergy to PLLA,&#xD;
             PDLLA or PLGA polymer&#xD;
&#xD;
          -  Previous enrollment in this trial&#xD;
&#xD;
          -  Patient's inability to fully cooperate with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Byrne, MB BCh PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Byrne, MB BCh PhD</last_name>
    <phone>+49 89 1218</phone>
    <phone_ext>4587</phone_ext>
    <email>byrne@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvatore Cassese, MD</last_name>
    <phone>+49 89 1218</phone>
    <phone_ext>4578</phone_ext>
    <email>Cassese@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Byrne, MB BCh PhD</last_name>
      <phone>+49-89-1218-</phone>
      <phone_ext>4587</phone_ext>
      <email>byrne@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Salvatore Cassese, MD</last_name>
      <phone>+49-89-1218-</phone>
      <phone_ext>4578</phone_ext>
      <email>cassese@dhm.mhn.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De novo stenosis</keyword>
  <keyword>bioresorbable polymer coating</keyword>
  <keyword>bioresorbable polymer backbone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

